Hyperion Therapeutics™ is a seed-stage startup pharmaceutical company dedicated to the development of novel, accessible therapies that effectively slow or prevent vision loss in progressive, incurable blinding diseases.
Meet the Founders
Building an interdisciplinary team of world-renowned scientists, clinicians, and fellows
Jennings Luu, MD/PhD Fellow
Founder, President & Chief Executive Officer
Jennings is a senior MD/PhD doctoral fellow from the Case Western Reserve University Medical Scientist Training Program and principal investigator of a National Research Service Award fellowship from the National Eye Institute of the National Institutes of Health. He graduated Summa Cum Laude with a Bachelor of Science in Physiological Science from the University of California, Los Angeles and is completing physician-scientist training with a doctorate in Pharmacology under the mentorship of Dr. Palczewski in the Center for Translational Vision Research at University of California, Irvine. Jennings is an inventor of patents on proprietary drug formulations in our therapeutic pipeline.
Kris Palczewski, PhD
Co-Founder, Chairman of Advisory Board
Krzysztof (Kris) is an internationally renowned chemist, pharmacologist, and vision scientist and inventor of ~50 patents approved and pending, several of which are on the proprietary drug formulations in our therapeutic pipeline. He has authored >500 peer-reviewed articles in top-tier journals including Science, Nature, Neuron, and Proceedings of the National Academy of Sciences, which have been cited over 54,000 times with an H-index of 121. Kris is currently the Irving H. Leopold Chair and Donald Bren Distinguished Professor of Ophthalmology at the University of California, Irvine, and has received the unique distinction of being elected to both the National Academy of Medicine and the National Academy of Sciences.
Our Partners & Affiliates
Forming strategic partnerships across academia and industry for optimized capital efficiency
The Company augments its core scientific and business capabilities through strategic alliances with academic and industrial entities. Collaborations with the University of California, Irvine (UCI), Center for Translational Vision Research and Beall Applied Innovation provide the Company with access to world-class facilities, cutting-edge biotechnologies, intellectual property and proprietary research tools that serve as the bedrock of the Company’s drug discovery and development efforts.
Global partners are welcome to submit prospective inquiries to email@example.com
At Hyperion Therapeutics, we are building a talented team of passionate, self-motivated professionals who are dedicated to advancing the company mission, with a shared commitment to help bring new medications to market for our world's leading causes of blindness.
Stay tuned for open career and internship opportunities!